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Sir,
We read with great interest a recently published article in your
journal entitled ‘No association between germline allele-specific
expression of TGFBR1 and colorectal cancer risk in Caucasian and
Ashkenazi populations’ (Seguı ´ et al, 2011). Whereas an allelic
expression imbalance of the transforming growth factor-b type 1
receptor (TGFbR1) gene was reported in 2008 to be a strong risk
factor for colorectal cancer (CRC), with an odds ratio of 8.7 (Valle
et al, 2008), this new study coordinated by Valle and performed on
96 CRC patients and 90 controls shows that there is no difference
in blood TGFbR1 allelic expression between CRC patients and
controls. The authors indicated that the discrepancy between these
two studies may probably be explained by the difference in the
methods used for measuring the allelic expression, the first study
being based on the SNaPshot methodology, corresponding to
primer extension with dye-labelled dideoxynucleotides, the second
having been performed with pyrosequencing. We would like to
highlight the fact that, to determine whether or not TGFbR1 allelic
expression is a main CRC genetic factor conferring a high odds
ratio, the selection both of patients and controls is a critical issue.
The original report by Valle et al (2008) was based on CRC patients
corresponding either to sporadic CRC cases or to familial cases.
This new study (Seguı ´ et al, 2011) was based on unselected
microsatellite-stable CRC patients, without information regarding
age of tumour onset or familial history, and the control population
was not described. It is noteworthy that this was also a potential
limitation of the additional studies on TGFbR1 allelic imbalance in
CRC published since 2008 and reporting contradictory results
(Guda et al, 2009; Carvajal-Carmona et al, 2010; Pasche et al, 2010;
Tomsic et al, 2010).
Therefore, we conducted a prospective case–control study on
carefully selected patients and controls to clarify the real
contribution of TGFbR1 allelic imbalance in CRC. After informed
consent, patients were selected according to three different criteria
suggestive of an increased genetic risk for CRC: (i) CRC before
61 years of age (or high-risk adenoma before 51 years of age) with
a first-degree relative presenting with CRC; (ii) CRC before 51
years of age (or high-risk adenoma before 41 years of age); or
(iii) multiple primitive colorectal tumours in the same case, the
first one diagnosed before 61 years of age if cancer or before 51
years of age if high-risk adenoma. Exclusion criteria were (i) Lynch
syndrome defined on the basis of a germline deleterious MMR
gene mutation or a CRC with microsatellite instability arising in a
suggestive familial context; (ii) adenomatous polyposis defined as
the presence of at least 10 colorectal adenomatous polyps. The
controls, aged from 45 to 60 years, were CRC-free and had no
familial history of CRC in their first-degree relatives. Genomic
DNA was extracted from whole blood samples using the FlexiGene
kit (Qiagen, Courtaboeuf, France). As high-quality RNA is a
pre-requisite to perform such a study, blood samples were
collected on PAXgene tubes (Qiagen), stored at  201C and total
RNA was extracted within 1 month after blood collection, using the
PAXgene Blood RNA kit (Qiagen). To measure TGFbR1 allelic
1.75
1.50
1.25
1.00
R
a
t
i
o
 
o
f
 
T
G
F

R
1
 
a
l
l
e
l
i
c
 
e
x
p
r
e
s
s
i
o
n
0.75
0.50
Controls
(N=98)
Patients
(N=69)
Figure 1 Ratios of TGFbR1 allelic expression in 98 informative controls
and 69 patients. The median and inter-quartile range values are indicated by
continuous traits. The cutoff values, indicated as discontinuous lines, were
those defined according to Valle et al (2008). *Correspondence: Dr T Frebourg; E-mail: Frebourg@chu-rouen.fr
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tems, Meylan, France) described in the initial report of Valle et al
(2008). For each patient and control, genomic DNA was first
genotyped for the following four TGFbR1 SNPs: rs334348,
rs334349, rs1590 (in total linkage disequilibrium) and rs7871490,
to identify heterozygous individuals. After RT–PCR was per-
formed from total RNA using oligo-dT (New England Biolabs,
Ipswich, MA, USA) and reverse transcriptase SuperScript II
(Invitrogen, Cergy-Pontoise, France), allelic expression of TGFbR1
was measured, using SNaPshot, by normalising the ratio of the
allelic peaks obtained on RT–PCR with the ratio of the allele peaks
obtained on genomic DNA. The allelic expression was calculated
from the average of the ratio obtained for the four SNPs, when
individuals were informative for all these SNPs; for individuals
informative only for the rs7871490 SNP, the analysis was
performed on two independent RT–PCRs. Among 175 Caucasian
controls and 110 Caucasian patients genotyped for the four SNPs,
we measured allelic expression of TGFbR1 in 98 informative
controls (56%) and 69 informative patients (63%). Using the
SNaPshot analysis, we did not encounter any reproducibility
problem: for heterozygous individuals for the four SNPs (rs334348,
rs334349, rs1590 and rs7871490), we obtained consistent ratio
values between each SNP and, even for the rs7871490 SNP localised
in a repetitive sequence, we observed reproducible results between
two independent analyses (average s.d.¼0.075). Allelic expression
ratios ranged between 0.82 and 1.41 (mean 1.06) in controls and
between 0.77 and 1.45 (mean 1.07) in patients with the relative
same compacted distribution of values in both analysed groups
(see Figure 1). No significant difference in allelic expression ratios
between patients and controls was observed (Mann–Whitney test
P¼0.72; Student’s test P¼0.58; permutation test P¼0.56).
In conclusion, we confirmed by studying highly selected patients
and controls that allelic imbalance of the TGFbR1 is not a major
contributor to the genetic predisposition to CRC. Therefore,
measurement of TGFbR1 allelic imbalance has no clinical utility to
identify patients with high CRC genetic risk.
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